Observational studyBMC nephrology2026
Differential associations of transient hyperuricemia and transient hypouricemia with annual changes in estimated glomerular filtration rate in healthy participants: an observational study.
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysuricemia, encompassing both hyperuricemia (serum uric acid: SUA > 7 mg/dl) and hypouricemia (SUA ≤ 3 mg/dL), has been linked to cardio-renal risks, but it remains unclear whether consistent or transient dysuricemia contributes to the risk of chronic kidney disease (CKD). PURPOSE: To investigate whether consistent and transient dysuricemia influences annual changes in the estimated glomerular filtration rate (eGFR) in healthy participants.
methodsWe retrospectively analyzed 1142 healthy participants who underwent health checkups with at least four consecutive annual measurements of eGFR and SUA. Participants with consistently hyperuricemia, hypouricemia, or normouricemia (7 mg/dL ≥ SUA > 3 mg/dL) throughout follow-up were categorized as consistent hyperuricemia (n = 36), consistent hypouricemia (n = 8) and normouricemia (n = 759), respectively. Others were classified as transient hyperuricemia (n = 282) and transient hypouricemia (n = 57). Annualized eGFR decline was compared using ANOVA, and incident CKD stage 3 events were evaluated using χ² or Fisher's exact tests. Multivariable analyses were performed to examine the association between baseline SUA and subsequent renal outcomes.
resultsHyperuricemia was positively associated with obesity, liver dysfunction, dyslipidemia, and higher baseline eGFR compared with normouricemia, whereas hypouricemia showed negative associations with obesity and liver dysfunction. Transient hyperuricemia was significantly associated with obesity, liver dysfunction, and dyslipidemia relative to consistent normouricemia, while transient hypouricemia was negatively associated with obesity and liver dysfunction. Transient hyperuricemia exhibited significantly faster annual eGFR decline than normouricemia, while transient hypouricemia showed no significant difference. Baseline SUA ≥ 7 mg/dL was associated with higher baseline eGFR but predicted a significantly faster subsequent eGFR decline. In multivariable linear regression, baseline SUA level was independently associated with eGFR change, whereas baseline SUA status did not independently predict incident CKD stage 3.
conclusionTransient hyperuricemia, rather than transient hypouricemia, is associated with accelerated eGFR decline in healthy individuals. Baseline SUA provides prognostic information regarding renal function trajectory, but does not independently predict CKD stage 3, suggesting that SUA should be interpreted as a clinically useful marker of renal vulnerability rather than a proven causal factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.